Noxopharm (ASX:NOX) has announced an expanded work program for 2025 with its strategic partner, Melbourne’s Hudson Institute of Medical Research.

Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the US Patent and Trademark Office has allowed the issuance of a patent application covering the company's CHM CDH17 chimeric antigen receptor technology.

Australian clinical-stage biopharmaceutical company Radiopharm Theranostics (ASX:RAD) has announced a poster presentation at the European Molecular Imaging Meeting.

Race Oncology (ASX:RAC) has announced that Bellberry has approved a phase one clinical trial of RC220 bisantrene alone and combined with doxorubicin in patients with solid tumours.

Neurizon Therapeutics (ASX:NUZ) has updated investors on its ongoing engagement with the US FDA on lifting the clinical hold on the company's investigational new drug application for NUZ-001. 

Nyrada (ASX:NYR) has commenced recruitment for its phase one clinical trial of its lead drug candidate NYR-BI03.

OncoSil Medical (ASX:OSL) has announced the appointment of Shelley Steyn as chief financial officer, effective 5 May.

Australian biotechnology company Noxopharm (ASX:NOX) has engaged Doherty Clinical Trials to conduct its upcoming phase 1 HERACLES trial.

Telix Pharmaceuticals (ASX:TLX) has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine.

Proteomics International Laboratories (ASX:PIQ) has officially launched its first-in-class predictive test for diabetic kidney disease, PromarkerD, in Australia.

Argent BioPharma (ASX:RGT) has signed an agreement with Dr Shlomo Sadoun granting him exclusive rights to facilitate a commercial transaction for the company's Malta-based GMP-certified manufacturing facility.

Australian company Anatara Lifesciences (ASX:ANR) has updated investors on the GaRP-Irritable Bowel Syndrome phase 2 trial and the anti-obesity project.

PolyNovo (ASX:PNV) has announced that its chief executive officer, Swami Raote, will officially leave the company in June but will step down immediately.

Respiratory imaging technology company 4DMedical (ASX:4DX) has announced the renewal and extension of the contract for its pulmonary function software-as-a-service analysis with the Cleveland Clinic.

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that Dr James Campbell will succeed Steven Engle as its chair.

A new report by Telix says the tens of thousands of Australians could miss out on a new era of cancer treatment without action from the government to secure the viability of the nuclear medicine sector, including enforcing regulatory standards.

Medtech entrepreneurs are invited to showcase their innovations at the 2025 Early-Stage Innovation Forum (ESIF), a premier platform for emerging developers to present their cutting-edge solutions at the AusMedtech 2025 conference in Sydney 6 – 8 May.